Global Injectable Drug Delivery Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024
In this region, global injectable drug delivery is projected to reach USD 789.7 billion by 2024 from USD 330.6 billion in 2016, at a CAGR of 11.5% in the forecast period 2017 to 2024.
Based on geography, the global injectable drug delivery market is segmented into 5 geographical regions, such as,
North America,
South America,
Europe,
APAC,
MEA,
Global injectable drug delivery market competition by top players including –
Becton Dickinson and company is going to dominate the injectable drug delivery market following with Pfizer and Baxter International, Inc., along with others such as
Gerresheimer AG,
Schott AG,
Alkermes Plc.,
Eli Lilly and Company,
Sandoz,
Terumo Corporation,
Teva Pharmaceuticals Industries Ltd.,
Bespak, Antares Pharma,
Elcam Medical,
Haselmeier,
Mylan N.V.,
Novo Nordisk,
Owen Mumford Ltd,
Sanofi,
West Pharmaceutical Services, Inc,
Ypsomed Holding AG.
The global injectable drug delivery market is segmented on the basis of type, product type, application, usage pattern, mode of administration, end user, distribution channel, and geography.
The global injectable drug delivery market is segmented into 2 types, namely injectable drug delivery device and injectable drug delivery formulation.
Injectable drug delivery device market is segmented into conventional injection devices and self-injection devices.
The injectable drug delivery formulation is segmented into conventional drug delivery formulation and novel drug delivery formulation.
On the basis of application, the market is segmented into autoimmune disease, hormonal disorders, orphan diseases, oncology and others.
The autoimmune diseases segment is further sub segmented based on indications into rheumatoid arthritis, multiple sclerosis, Crohn’s disease, psoriasis and others.
Hormonal disorders are further segmented into indications such as diabetes, antithrombotic therapy, reproductive health diseases, anemia, osteoporosis and others.
On the basis of usage pattern, the market is segmented into curative care, immunization and other usage pattern.
On the basis of mode of administration, the market is segmented into skin, circulatory/muskoskeletal, organs and central nervous system.
On the basis of end users, the market is classified into hospitals and clinics, home healthcare, research laboratories, pharmaceutical and biotechnological companies and others.
Based on geography, the global injectable drug delivery market is segmented into 5 geographical regions, such as,
North America,
South America,
Europe,
APAC,
MEA,
Global injectable drug delivery market competition by top players including –
Becton Dickinson and company is going to dominate the injectable drug delivery market following with Pfizer and Baxter International, Inc., along with others such as
Gerresheimer AG,
Schott AG,
Alkermes Plc.,
Eli Lilly and Company,
Sandoz,
Terumo Corporation,
Teva Pharmaceuticals Industries Ltd.,
Bespak, Antares Pharma,
Elcam Medical,
Haselmeier,
Mylan N.V.,
Novo Nordisk,
Owen Mumford Ltd,
Sanofi,
West Pharmaceutical Services, Inc,
Ypsomed Holding AG.
The global injectable drug delivery market is segmented on the basis of type, product type, application, usage pattern, mode of administration, end user, distribution channel, and geography.
The global injectable drug delivery market is segmented into 2 types, namely injectable drug delivery device and injectable drug delivery formulation.
Injectable drug delivery device market is segmented into conventional injection devices and self-injection devices.
The injectable drug delivery formulation is segmented into conventional drug delivery formulation and novel drug delivery formulation.
On the basis of application, the market is segmented into autoimmune disease, hormonal disorders, orphan diseases, oncology and others.
The autoimmune diseases segment is further sub segmented based on indications into rheumatoid arthritis, multiple sclerosis, Crohn’s disease, psoriasis and others.
Hormonal disorders are further segmented into indications such as diabetes, antithrombotic therapy, reproductive health diseases, anemia, osteoporosis and others.
On the basis of usage pattern, the market is segmented into curative care, immunization and other usage pattern.
On the basis of mode of administration, the market is segmented into skin, circulatory/muskoskeletal, organs and central nervous system.
On the basis of end users, the market is classified into hospitals and clinics, home healthcare, research laboratories, pharmaceutical and biotechnological companies and others.
1. INTRODUCTION
1.1. OVERVIEW OF GLOBAL INJECTABLEDRUG DELIVERY MARKET
1.2. CURRENCY AND PRICING
1.3. LIMITATION
1.4. MARKETS COVERED
2. MARKET SEGMENTATION
2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURCES
2.8. ASSUMPTIONS
3. MARKET OVERVIEW
3.1. DRIVERS
3.1.1. RISING CASES OF CHRONIC DISEASES
3.1.2. RISING DEMAND OF SELF-INJECTION DEVICES
3.1.3. GROWTH OF BIOLOGICS MARKET
3.1.4. TECHNOLOGICAL ADVANCEMENTS AND INNOVATIONS IN DRUG DELIVERY MARKET
3.2. RESTRAINTS
3.2.1. NEEDLESTICK INJURIES AND INFECTIONS
3.2.2. HIGH COST OF DEVELOPMENT
3.2.3. STRICT REGULATORY FRAMEWORK
3.3. OPPORTUNITY
3.3.1. INCREASING DEMAND FOR GENERIC AND BIOSIMILAR DRUGS
3.3.1.1. GENERICS
3.3.1.2. BIOSIMILARS
3.3.2. INCREASING DEMAND FOR CONTRACEPTIVE INJECTABLES
3.3.3. INCREASING DEMAND FOR SELF-ADMINISTRATION OF DRUGS
3.4. CHALLENGES
3.4.1. ALTERNATIVE ROUTE OF DRUG ADMINISTRATION
3.4.2. PRODUCT RECALL
3.4.3. STABILITY OF PRODUCTS
3.4.4. STERILITY OF INJECTIONS
4. EXECUTIVE SUMMARY
5. PREMIUM INSIGHTS
6. GLOBAL INJECTABLE DRUG DELIVERY MARKET, REGULATORY
6.1. OVERVIEW
6.2. U.S. FDA APPROVAL
6.3. CE MARKING (EUROPEAN CONFORMITY)
6.4. EM (EUROPEAN MEDICINE AGENCY)
7. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY TYPE
7.1. OVERVIEW
7.2. INJECTable DRUG DELIVERY DEVICES
7.2.1. CONVENTIONAL INJECTION DEVICES
7.2.2. SELF INJECTION DEVICES
7.2.2.1. NEEDLE FREE INJECTORS (NFI)
7.2.2.2. AUTO INJECTORS
7.2.2.3. PEN INJECTORS
7.2.2.4. WEARABLE INJECTORS
7.3. INJECTable DRUG DELIVERY FORMULATION
7.3.1. CONVENTIONAL DRUG DELIVERY FORMULATIONS
7.3.1.1. SOLUTIONS
7.3.1.2. RECONSTITUTED/LYOPHILIZED FORMULATIONS
7.3.1.3. SUSPENSIONS
7.3.1.4. EMULSIONS
7.3.2. NOVEL DRUG DELIVERY FORMULATIONS
7.3.2.1. COLLOIDAL DISPERSIONS
7.3.2.2. MICROPARTICLES
7.3.2.3. LONG ACTING INJECTION FORMULATION
8. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION
8.1. OVERVIEW
8.2. GLOBAL INJECTable DRUG DELIVERY MARKET, BY APPLICATION
8.3. HORMONAL DISORDERS
8.3.1. INJECTable DRUGS FOR DIABETES
8.3.2. INJECTable DRUGS FOR ANEMIA
8.3.3. INJECTable DRUGS FOR REPRODUCTIVE HEALTH DISEASE
8.3.4. INJECTable DRUGS FOR ANTITHROMBOTIC/THROMBOLYTIC THERAPY
8.3.5. INJECTable DRUGS FOR OSTEOPOROSIS
8.3.6. INJECTable DRUGS FOR GROWTH HORMONE DISORDERS (GHD)
8.4. ONCOLOGY
8.5. AUTOIMMUNE DISEASES
8.5.1. INJECTable DRUGS FOR RHEUMATOID ARTHRITIS
8.5.2. INJECTable DRUGS FOR MULTIPLE SCLEROSIS
8.5.3. INJECTable DRUGS FOR CROHN’S DISEASES
8.5.4. INJECTable DRUGS FOR PSORIASIS
8.5.5. INJECTable DRUGS FOR OTHER AUTOIMMUNE DISEASES
8.6. ORPHAN DISEASE
8.7. OTHER APPLICATIONS
8.7.1. INJECTable DRUGS FOR PAIN MANAGEMENT
8.7.2. INJECTable DRUGS FOR ALLERGY TREATMENT
8.7.3. INJECTable DRUGS FOR AESTHETIC TREATMENTS
8.7.4. INJECTable DRUGS FOR HEPATITIS C
8.7.5. INJECTable DRUGS FOR HEMOPHILIA
9. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN
9.1. OVERVIEW
9.2. CURATIVE CARE
9.3. IMMUNIZATIONS
9.4. OTHER USAGE PATTERN
10. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION
10.1. OVERVIEW
10.2. SKIN
10.3. CIRCULATORY/ MUSKOSKELETAL
10.4. ORGANS
10.5. CENTRAL NERVOUS SYSTEM
11. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY END USER
11.1. OVERVIEW
11.2. HOSPITALS AND CLINICS
11.3. HOME HEALTHCARE SETTINGS
11.4. RESEARCH LABORATORIES
11.5. PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES
11.6. OTHER END USERS
12. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL
12.1. OVERVIEW
12.1.1. HOSPITAL PHARMACY
12.1.2. PHARMACY STORES
12.1.3. DIRECT TENDER
12.1.4. ONLINE PHARMACY
13. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY
13.1. OVERVIEW
13.2. NORTH AMERICA INJECTable DRUG DELIVERY MARKET
13.2.1. U.S. INJECTable DRUG DELIVERY MARKET
13.2.2. CANADA INJECTable DRUG DELIVERY MARKET
13.2.3. MEXICO INJECTable DRUG DELIVERY MARKET
13.3. EUROPE INJECTable DRUG DELIVERY MARKET
13.3.1. GERMANY INJECTable DRUG DELIVERY MARKET
13.3.2. FRANCE INJECTable DRUG DELIVERY MARKET
13.3.3. UK INJECTable DRUG DELIVERY MARKET
13.3.4. ITALY INJECTable DRUG DELIVERY MARKET
13.3.5. SWITZERLAND INJECTable DRUG DELIVERY MARKET
13.3.6. SPAIN INJECTable DRUG DELIVERY MARKET
13.3.7. NETHERLAND INJECTable DRUG DELIVERY MARKET
13.3.8. RUSSIA INJECTable DRUG DELIVERY MARKET
13.3.9. TURKEY INJECTable DRUG DELIVERY MARKET
13.3.10. BELGIUM INJECTable DRUG DELIVERY MARKET
13.3.11. REST OF EUROPE INJECTable DRUG DELIVERY MARKET
13.4. APAC INJECTable DRUG DELIVERY MARKET
13.4.1. JAPAN INJECTable DRUG DELIVERY MARKET
13.4.2. CHINA INJECTable DRUG DELIVERY MARKET
13.4.3. SOUTH KOREA INJECTable DRUG DELIVERY MARKET
13.4.4. INDIA INJECTable DRUG DELIVERY MARKET
13.4.5. AUSTRALIA INJECTable DRUG DELIVERY MARKET
13.4.6. SINGAPORE INJECTable DRUG DELIVERY MARKET
13.4.7. THAILAND INJECTable DRUG DELIVERY MARKET
13.4.8. MALAYSIA INJECTable DRUG DELIVERY MARKET
13.4.9. INDONESIA INJECTable DRUG DELIVERY MARKET
13.4.10. PHILIPPINES INJECTable DRUG DELIVERY MARKET
13.4.11. REST OF APAC INJECTable DRUG DELIVERY MARKET
13.5. SOUTH AMERICA INJECTable DRUG DELIVERY MARKET
13.5.1. BRAZIL INJECTable DRUG DELIVERY MARKET
13.5.2. REST OF SOUTH AMERICA INJECTable DRUG DELIVERY MARKET
13.6. MEA INJECTable DRUG DELIVERY MARKET
13.6.1. SOUTH AFRICA INJECTable DRUG DELIVERY MARKET
13.6.2. REST OF MEA INJECTable DRUG DELIVERY MARKET
14. GLOBAL INJECTABLE DRUG DELIVERY MARKET, COMPANY SHARE
14.1. COMPANY SHARE ANALYSIS: GLOBAL
15. COMPANY PROFILES
15.1. BECTON, DICKINSON AND COMPANY
15.1.1. COMPANY OVERVIEW
15.1.1.1. DRIVERS EXPLAINED
15.1.1.2. WEAKNESSES EXPLAINED
15.1.1.3. OPPURTUNITIES EXPLAINED
15.1.1.4. THREATS EXPLAINED
15.1.2. PRODUCT PORTFOLIO
15.1.3. RECENT DEVELOPMENTS
15.2. PFIZER
15.2.1. COMPANY OVERVIEW
15.2.1.1. DRIVERS EXPLAINED
15.2.1.2. WEAKNESSES EXPLAINED
15.2.1.3. OPPURTUNITIES EXPLAINED
15.2.1.4. THREATS EXPLAINED
15.2.2. PRODUCT PORTFOLIO
15.2.3. RECENT DEVELOPMENTS
15.3. BAXTER INTERNATIONAL
15.3.1. COMPANY OVERVIEW
15.3.1.1. DRIVERS EXPLAINED
15.3.1.2. WEAKNESSES EXPLAINED
15.3.1.3. OPPURTUNITIES EXPLAINED
15.3.1.4. THREATS EXPLAINED
15.3.2. PRODUCT PORTFOLIO
15.3.3. RECENT DEVELOPMENTS
15.4. GERRESHEIMER AG
15.4.1. COMPANY OVERVIEW
15.4.2. PRODUCT PORTFOLIO
15.4.3. RECENT DEVELOPMENTS
15.5. SCHOTT AG INC.
15.5.1. COMPANY OVERVIEW
15.5.2. PRODUCT PORTFOLIO
15.5.3. RECENT DEVELOPMENTS
15.6. ALKERMES INC.
15.6.1. COMPANY OVERVIEW
15.6.2. PRODUCT PORTFOLIO
15.6.3. RECENT DEVELOPMENTS
15.7. ANTARES PHARMA
15.7.1. COMPANY OVERVIEW
15.7.2. PRODUCT PORTFOLIO
15.7.3. RECENT DEVELOPMENTS
15.8. BESPAK (SUBSIDIARY OF CONSORT MEDICAL COMPANY)
15.8.1. COMPANY OVERVIEW
15.8.2. PRODUCT PORTFOLIO
15.8.3. RECENT DEVELOPMENTS
15.9. ELCAM MEDICAL
15.9.1. COMPANY OVERVIEW
15.9.2. PRODUCT PORTFOLIO
15.9.3. RECENT DEVELOPMENTS
15.10. ELI LILLY AND COMPANY
15.10.1. COMPANY OVERVIEW
15.10.1.1. DRIVERS EXPLAINED
15.10.1.2. WEAKNESSES EXPLAINED
15.10.1.3. OPPURTUNITIES EXPLAINED
15.10.1.4. THREATS EXPLAINED
15.10.2. PRODUCT PORTFOLIO
15.10.3. RECENT DEVELOPMENTS
15.11. HASELMEIER
15.11.1. COMPANY OVERVIEW
15.11.2. PRODUCT PORTFOLIO
15.11.3. RECENT DEVELOPMENTS
15.12. MYLAN N.V.
15.12.1. COMPANY OVERVIEW
15.12.2. PRODUCT PORTFOLIO
15.12.3. RECENT DEVELOPMENTS
15.13. NOVO NORDISK
15.13.1. COMPANY OVERVIEW
15.13.2. PRODUCT PORTFOLIO
15.13.3. RECENT DEVELOPMENTS
15.14. OWEN MUMFORD LTD
15.14.1. COMPANY OVERVIEW
15.14.2. PRODUCT PORTFOLIO
15.14.3. RECENT DEVELOPMENTS
15.15. SANDOZ INTERNATIONAL GMBH
15.15.1. COMPANY OVERVIEW
15.15.2. PRODUCT PORTFOLIO
15.15.3. RECENT DEVELOPMENTS
15.16. SANOFI
15.16.1. COMPANY OVERVIEW
15.16.2. PRODUCT PORTFOLIO
15.16.3. RECENT DEVELOPMENTS
15.17. TERUMO CORPORATION
15.17.1. COMPANY OVERVIEW
15.17.2. PRODUCT PORTFOLIO
15.17.3. RECENT DEVELOPMENTS
15.18. TEVA PHARMACEUTICAL
15.18.1. COMPANY OVERVIEW
15.18.1.1. DRIVERS EXPLAINED
15.18.1.2. WEAKNESSES EXPLAINED
15.18.1.3. OPPURTUNITIES EXPLAINED
15.18.1.4. THREATS EXPLAINED
15.18.2. PRODUCT PORTFOLIO
15.18.3. RECENT DEVELOPMENTS
15.19. WEST PHARMACEUTICAL SERVICES, INC
15.19.1. COMPANY OVERVIEW
15.19.2. PRODUCT PORTFOLIO
15.19.3. RECENT DEVELOPMENTS
15.20. YPSOMED HOLDING AG
15.20.1. COMPANY OVERVIEW
15.20.2. PRODUCT PORTFOLIO
15.20.3. RECENT DEVELOPMENTS
16. RELATED REPORTS
1.1. OVERVIEW OF GLOBAL INJECTABLEDRUG DELIVERY MARKET
1.2. CURRENCY AND PRICING
1.3. LIMITATION
1.4. MARKETS COVERED
2. MARKET SEGMENTATION
2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURCES
2.8. ASSUMPTIONS
3. MARKET OVERVIEW
3.1. DRIVERS
3.1.1. RISING CASES OF CHRONIC DISEASES
3.1.2. RISING DEMAND OF SELF-INJECTION DEVICES
3.1.3. GROWTH OF BIOLOGICS MARKET
3.1.4. TECHNOLOGICAL ADVANCEMENTS AND INNOVATIONS IN DRUG DELIVERY MARKET
3.2. RESTRAINTS
3.2.1. NEEDLESTICK INJURIES AND INFECTIONS
3.2.2. HIGH COST OF DEVELOPMENT
3.2.3. STRICT REGULATORY FRAMEWORK
3.3. OPPORTUNITY
3.3.1. INCREASING DEMAND FOR GENERIC AND BIOSIMILAR DRUGS
3.3.1.1. GENERICS
3.3.1.2. BIOSIMILARS
3.3.2. INCREASING DEMAND FOR CONTRACEPTIVE INJECTABLES
3.3.3. INCREASING DEMAND FOR SELF-ADMINISTRATION OF DRUGS
3.4. CHALLENGES
3.4.1. ALTERNATIVE ROUTE OF DRUG ADMINISTRATION
3.4.2. PRODUCT RECALL
3.4.3. STABILITY OF PRODUCTS
3.4.4. STERILITY OF INJECTIONS
4. EXECUTIVE SUMMARY
5. PREMIUM INSIGHTS
6. GLOBAL INJECTABLE DRUG DELIVERY MARKET, REGULATORY
6.1. OVERVIEW
6.2. U.S. FDA APPROVAL
6.3. CE MARKING (EUROPEAN CONFORMITY)
6.4. EM (EUROPEAN MEDICINE AGENCY)
7. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY TYPE
7.1. OVERVIEW
7.2. INJECTable DRUG DELIVERY DEVICES
7.2.1. CONVENTIONAL INJECTION DEVICES
7.2.2. SELF INJECTION DEVICES
7.2.2.1. NEEDLE FREE INJECTORS (NFI)
7.2.2.2. AUTO INJECTORS
7.2.2.3. PEN INJECTORS
7.2.2.4. WEARABLE INJECTORS
7.3. INJECTable DRUG DELIVERY FORMULATION
7.3.1. CONVENTIONAL DRUG DELIVERY FORMULATIONS
7.3.1.1. SOLUTIONS
7.3.1.2. RECONSTITUTED/LYOPHILIZED FORMULATIONS
7.3.1.3. SUSPENSIONS
7.3.1.4. EMULSIONS
7.3.2. NOVEL DRUG DELIVERY FORMULATIONS
7.3.2.1. COLLOIDAL DISPERSIONS
7.3.2.2. MICROPARTICLES
7.3.2.3. LONG ACTING INJECTION FORMULATION
8. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION
8.1. OVERVIEW
8.2. GLOBAL INJECTable DRUG DELIVERY MARKET, BY APPLICATION
8.3. HORMONAL DISORDERS
8.3.1. INJECTable DRUGS FOR DIABETES
8.3.2. INJECTable DRUGS FOR ANEMIA
8.3.3. INJECTable DRUGS FOR REPRODUCTIVE HEALTH DISEASE
8.3.4. INJECTable DRUGS FOR ANTITHROMBOTIC/THROMBOLYTIC THERAPY
8.3.5. INJECTable DRUGS FOR OSTEOPOROSIS
8.3.6. INJECTable DRUGS FOR GROWTH HORMONE DISORDERS (GHD)
8.4. ONCOLOGY
8.5. AUTOIMMUNE DISEASES
8.5.1. INJECTable DRUGS FOR RHEUMATOID ARTHRITIS
8.5.2. INJECTable DRUGS FOR MULTIPLE SCLEROSIS
8.5.3. INJECTable DRUGS FOR CROHN’S DISEASES
8.5.4. INJECTable DRUGS FOR PSORIASIS
8.5.5. INJECTable DRUGS FOR OTHER AUTOIMMUNE DISEASES
8.6. ORPHAN DISEASE
8.7. OTHER APPLICATIONS
8.7.1. INJECTable DRUGS FOR PAIN MANAGEMENT
8.7.2. INJECTable DRUGS FOR ALLERGY TREATMENT
8.7.3. INJECTable DRUGS FOR AESTHETIC TREATMENTS
8.7.4. INJECTable DRUGS FOR HEPATITIS C
8.7.5. INJECTable DRUGS FOR HEMOPHILIA
9. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN
9.1. OVERVIEW
9.2. CURATIVE CARE
9.3. IMMUNIZATIONS
9.4. OTHER USAGE PATTERN
10. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION
10.1. OVERVIEW
10.2. SKIN
10.3. CIRCULATORY/ MUSKOSKELETAL
10.4. ORGANS
10.5. CENTRAL NERVOUS SYSTEM
11. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY END USER
11.1. OVERVIEW
11.2. HOSPITALS AND CLINICS
11.3. HOME HEALTHCARE SETTINGS
11.4. RESEARCH LABORATORIES
11.5. PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES
11.6. OTHER END USERS
12. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL
12.1. OVERVIEW
12.1.1. HOSPITAL PHARMACY
12.1.2. PHARMACY STORES
12.1.3. DIRECT TENDER
12.1.4. ONLINE PHARMACY
13. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY
13.1. OVERVIEW
13.2. NORTH AMERICA INJECTable DRUG DELIVERY MARKET
13.2.1. U.S. INJECTable DRUG DELIVERY MARKET
13.2.2. CANADA INJECTable DRUG DELIVERY MARKET
13.2.3. MEXICO INJECTable DRUG DELIVERY MARKET
13.3. EUROPE INJECTable DRUG DELIVERY MARKET
13.3.1. GERMANY INJECTable DRUG DELIVERY MARKET
13.3.2. FRANCE INJECTable DRUG DELIVERY MARKET
13.3.3. UK INJECTable DRUG DELIVERY MARKET
13.3.4. ITALY INJECTable DRUG DELIVERY MARKET
13.3.5. SWITZERLAND INJECTable DRUG DELIVERY MARKET
13.3.6. SPAIN INJECTable DRUG DELIVERY MARKET
13.3.7. NETHERLAND INJECTable DRUG DELIVERY MARKET
13.3.8. RUSSIA INJECTable DRUG DELIVERY MARKET
13.3.9. TURKEY INJECTable DRUG DELIVERY MARKET
13.3.10. BELGIUM INJECTable DRUG DELIVERY MARKET
13.3.11. REST OF EUROPE INJECTable DRUG DELIVERY MARKET
13.4. APAC INJECTable DRUG DELIVERY MARKET
13.4.1. JAPAN INJECTable DRUG DELIVERY MARKET
13.4.2. CHINA INJECTable DRUG DELIVERY MARKET
13.4.3. SOUTH KOREA INJECTable DRUG DELIVERY MARKET
13.4.4. INDIA INJECTable DRUG DELIVERY MARKET
13.4.5. AUSTRALIA INJECTable DRUG DELIVERY MARKET
13.4.6. SINGAPORE INJECTable DRUG DELIVERY MARKET
13.4.7. THAILAND INJECTable DRUG DELIVERY MARKET
13.4.8. MALAYSIA INJECTable DRUG DELIVERY MARKET
13.4.9. INDONESIA INJECTable DRUG DELIVERY MARKET
13.4.10. PHILIPPINES INJECTable DRUG DELIVERY MARKET
13.4.11. REST OF APAC INJECTable DRUG DELIVERY MARKET
13.5. SOUTH AMERICA INJECTable DRUG DELIVERY MARKET
13.5.1. BRAZIL INJECTable DRUG DELIVERY MARKET
13.5.2. REST OF SOUTH AMERICA INJECTable DRUG DELIVERY MARKET
13.6. MEA INJECTable DRUG DELIVERY MARKET
13.6.1. SOUTH AFRICA INJECTable DRUG DELIVERY MARKET
13.6.2. REST OF MEA INJECTable DRUG DELIVERY MARKET
14. GLOBAL INJECTABLE DRUG DELIVERY MARKET, COMPANY SHARE
14.1. COMPANY SHARE ANALYSIS: GLOBAL
15. COMPANY PROFILES
15.1. BECTON, DICKINSON AND COMPANY
15.1.1. COMPANY OVERVIEW
15.1.1.1. DRIVERS EXPLAINED
15.1.1.2. WEAKNESSES EXPLAINED
15.1.1.3. OPPURTUNITIES EXPLAINED
15.1.1.4. THREATS EXPLAINED
15.1.2. PRODUCT PORTFOLIO
15.1.3. RECENT DEVELOPMENTS
15.2. PFIZER
15.2.1. COMPANY OVERVIEW
15.2.1.1. DRIVERS EXPLAINED
15.2.1.2. WEAKNESSES EXPLAINED
15.2.1.3. OPPURTUNITIES EXPLAINED
15.2.1.4. THREATS EXPLAINED
15.2.2. PRODUCT PORTFOLIO
15.2.3. RECENT DEVELOPMENTS
15.3. BAXTER INTERNATIONAL
15.3.1. COMPANY OVERVIEW
15.3.1.1. DRIVERS EXPLAINED
15.3.1.2. WEAKNESSES EXPLAINED
15.3.1.3. OPPURTUNITIES EXPLAINED
15.3.1.4. THREATS EXPLAINED
15.3.2. PRODUCT PORTFOLIO
15.3.3. RECENT DEVELOPMENTS
15.4. GERRESHEIMER AG
15.4.1. COMPANY OVERVIEW
15.4.2. PRODUCT PORTFOLIO
15.4.3. RECENT DEVELOPMENTS
15.5. SCHOTT AG INC.
15.5.1. COMPANY OVERVIEW
15.5.2. PRODUCT PORTFOLIO
15.5.3. RECENT DEVELOPMENTS
15.6. ALKERMES INC.
15.6.1. COMPANY OVERVIEW
15.6.2. PRODUCT PORTFOLIO
15.6.3. RECENT DEVELOPMENTS
15.7. ANTARES PHARMA
15.7.1. COMPANY OVERVIEW
15.7.2. PRODUCT PORTFOLIO
15.7.3. RECENT DEVELOPMENTS
15.8. BESPAK (SUBSIDIARY OF CONSORT MEDICAL COMPANY)
15.8.1. COMPANY OVERVIEW
15.8.2. PRODUCT PORTFOLIO
15.8.3. RECENT DEVELOPMENTS
15.9. ELCAM MEDICAL
15.9.1. COMPANY OVERVIEW
15.9.2. PRODUCT PORTFOLIO
15.9.3. RECENT DEVELOPMENTS
15.10. ELI LILLY AND COMPANY
15.10.1. COMPANY OVERVIEW
15.10.1.1. DRIVERS EXPLAINED
15.10.1.2. WEAKNESSES EXPLAINED
15.10.1.3. OPPURTUNITIES EXPLAINED
15.10.1.4. THREATS EXPLAINED
15.10.2. PRODUCT PORTFOLIO
15.10.3. RECENT DEVELOPMENTS
15.11. HASELMEIER
15.11.1. COMPANY OVERVIEW
15.11.2. PRODUCT PORTFOLIO
15.11.3. RECENT DEVELOPMENTS
15.12. MYLAN N.V.
15.12.1. COMPANY OVERVIEW
15.12.2. PRODUCT PORTFOLIO
15.12.3. RECENT DEVELOPMENTS
15.13. NOVO NORDISK
15.13.1. COMPANY OVERVIEW
15.13.2. PRODUCT PORTFOLIO
15.13.3. RECENT DEVELOPMENTS
15.14. OWEN MUMFORD LTD
15.14.1. COMPANY OVERVIEW
15.14.2. PRODUCT PORTFOLIO
15.14.3. RECENT DEVELOPMENTS
15.15. SANDOZ INTERNATIONAL GMBH
15.15.1. COMPANY OVERVIEW
15.15.2. PRODUCT PORTFOLIO
15.15.3. RECENT DEVELOPMENTS
15.16. SANOFI
15.16.1. COMPANY OVERVIEW
15.16.2. PRODUCT PORTFOLIO
15.16.3. RECENT DEVELOPMENTS
15.17. TERUMO CORPORATION
15.17.1. COMPANY OVERVIEW
15.17.2. PRODUCT PORTFOLIO
15.17.3. RECENT DEVELOPMENTS
15.18. TEVA PHARMACEUTICAL
15.18.1. COMPANY OVERVIEW
15.18.1.1. DRIVERS EXPLAINED
15.18.1.2. WEAKNESSES EXPLAINED
15.18.1.3. OPPURTUNITIES EXPLAINED
15.18.1.4. THREATS EXPLAINED
15.18.2. PRODUCT PORTFOLIO
15.18.3. RECENT DEVELOPMENTS
15.19. WEST PHARMACEUTICAL SERVICES, INC
15.19.1. COMPANY OVERVIEW
15.19.2. PRODUCT PORTFOLIO
15.19.3. RECENT DEVELOPMENTS
15.20. YPSOMED HOLDING AG
15.20.1. COMPANY OVERVIEW
15.20.2. PRODUCT PORTFOLIO
15.20.3. RECENT DEVELOPMENTS
16. RELATED REPORTS
LIST OF TABLES
Table 1 EXAMPLES OF TECHNOLOGICAL ADVANCEMENTS ()(2013- 2017)
Table 2 NUMBER OF NEEDLESTICK INJURIES
Table 3 LIST OF PRODUCT RECALL DRUGS
Table 4 LIST OF DIFFERENT TYPES OF APPROVAL FOR DIFFERENT COUNTRIES
Table 5 GLOBAL INJECTable DRUG DELIVERY MARKET, BY TYPE, 2015 – 2024(USD MILLION)
Table 6 GLOBAL INJECTable DRUG DELIVERY DEVICES MARKET, BY TYPE, 2015 – 2024 (USD MILLION)
Table 7 GLOBAL CONVENTIONAL DRUG DELIVERY MARKET, BY MATERIAL, 2015 – 2024 (USD MILLION)
Table 8 GLOBAL CONVENTIONAL DRUG DELIVERY MARKET, BY PRODUCT, 2015 – 2024 (USD MILLION)
Table 9 GLOBAL CONVENTIONAL DRUG DELIVERY MARKET, BY USABILITY, 2015 – 2024 (USD MILLION)
Table 10 GLOBAL SELF INJECTION DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 11 GLOBAL NEEDLE FREE INJECTOR DEVICES MARKET, BY PRODUCT, 2015 – 2024 (USD MILLION)
Table 12 GLOBAL NEEDLE FREE INJECTOR DEVICES MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)
Table 13 GLOBAL NEEDLE FREE INJECTORS DEVICE ARKET, BY USABILITY, 2015 – 2024 (USD MILLION)
Table 14 GLOBAL AUTO INJECTOR DEVICES MARKET, BY PRODUCT, 2015 – 2024 (USD MILLION)
Table 15 GLOBAL AUTO INJECTOR DEVICES MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)
Table 16 GLOBAL AUTO INJECTOR DEVICES MARKET, BY DESIGN, 2015 – 2024 (USD MILLION)
Table 17 GLOBAL AUTO INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024 (USD MILLION)
Table 18 GLOBAL PEN INJECTOR DEVICES MARKET, BY PRODUCT, 2015 – 2024 (USD MILLION)
Table 19 GLOBAL PEN INJECTOR DEVICES MARKET, BY DESIGN, 2015 – 2024 (USD MILLION)
Table 20 GLOBAL PEN INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024 (USD MILLION)
Table 21 GLOBAL INJECTable DRUG DELIVERY FORMULATION MARKET, BY TYPE, 2015 – 2024 (USD MILLION)
Table 22 LIST OF SOME OF THE LYOPHILIZED FORMULATIONS
Table 23 LIST OF SOME OF THE EMULSIONS
Table 24 GLOBAL CONVENTIONAL DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 25 GLOBAL NOVEL DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE,2015 – 2024 (USD MILLION)
Table 26 GLOBAL COLLOIDAL NOVEL DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 27 LIST OF SOME OF THE NIOSOMES
Table 28 LIST OF SOME OF THE POLYMERIC MIXED MICELLES DRUG MANUFACTURER
Table 29 LIST OF NANOSUSPENSION DRUG MANUFACTURER
Table 30 LIST OF SOME OF THE NANOEMULSIONS/MICROEMULSIONS DRUG MANUFACTURER
Table 31 LIST OF SOME OF THE SOLID LIPID NANOPARTICLES DRUG MANUFACTURER
Table 32 GLOBAL NANOPARTICLE COLLOIDAL DRUG DELIVERY FORMULATION MARKET, BY PRODUCT, 2015 – 2024 (USD MILLION)
Table 33 LIST OF SOME OF THE MICROSPHERES DRUG MANUFACTURER
Table 34 GLOBAL MICROPARTICLES COLLOIDAL NOVEL DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 35 LIST OF SOME OF THE FIRST GENERATION LONG ACTING INJECTION
Table 36 LIST OF SOME OF THE SECOND GENERATION LONG ACTING INJECTION:
Table 37 GLOBAL INJECTable DRUG DELIVERY APPLICATION MARKET, BY TYPE, 2015 – 2024 (USD MILLION)
Table 38 GLOBAL HORMONAL DISORDERS INJECTable DRUG DELIVERY APPLICATION MARKET, BY TYPE, 2015 – 2024 (USD BILLION)
Table 39 GLOBAL AUTOIMMUNE DISEASE INJECTable DRUG DELIVERY APPLICATION MARKET, BY TYPE, 2015 – 2024 (USD BILLION)
Table 40 LIST OF ORPHAN DISEASE IN INDIA (2010)
Table 41 GLOBAL OTHERS INJECTable DRUG DELIVERY APPLICATION MARKET, BY TYPE, 2015 – 2024 (USD BILLION)
Table 42 GLOBALINJECTable DRUG DELIVERY USAGE PATTERN MARKET, BY TYPE, 2015 – 2024 (USD MILLION)
Table 43 GLOBAL INJECTable DRUG DELIVERY MODE OF ADMINISTRATION MARKET, BY TYPE, 2015 – 2024 (USD MILLION)
Table 44 GLOBAL INJECTable DRUG DELIVERY MARKET, BY END USER, 2015– 2024 (USD MILLION)
Table 45 GLOBAL INJECTable DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
Table 46 GLOBAL INJECTable DRUG DELIVERY MARKET, BY GEOGRAPHY, 2015 – 2024 (USD MILLION)
Table 47 NORTH AMERICA INJECTable DRUG DELIVERY MARKET, BY COUNTRY, 2015 – 2024 (USD MILLION)
Table 48 NORTH AMERICA INJECTable DRUG DELIVERY MARKET, BY TYPE, 2015 – 2024(USD MILLION)
Table 49 NORTH AMERICA INJECTable DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 50 NORTH AMERICA CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY MATERIAL,2015 – 2024(USD MILLION)
Table 51 NORTH AMERICA CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION)
Table 52 NORTH AMERICA CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 53 NORTH AMERICA SELF INJECTION DEVICE MARKET, BY TYPE, 2015 – 2024(USD MILLION)
Table 54 NORTH AMERICA NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY PRODUCT,2015 – 2024(USD MILLION)
Table 55 NORTH AMERICA NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)
Table 56 NORTH AMERICA NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 57 NORTH AMERICA AUTO INJECTORSDEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)
Table 58 NORTH AMERICA AUTO INJECTORS DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)
Table 59 NORTH AMERICA AUTO INJECTORS DEVICE MARKET, BY DESIGN, 2015 – 2024(USD MILLION)
Table 60 NORTH AMERICA AUTO INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 61 NORTH AMERICA PEN INJECTORS DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)
Table 62 NORTH AMERICA PEN INJECTORS DEVICE MARKET, BY DESIGN, 2015 – 2024(USD MILLION)
Table 63 NORTH AMERICA PEN INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 64 NORTH AMERICA INJECTable DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE, 2015– 2024 (USD MILLION)
Table 65 NORTH AMERICA CONVENTIONALDRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)
Table 66 NORTH AMERICA NOVELDRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)
Table 67 NORTH AMERICA COLLOIDALDISPERSION DRUG DELIVERY FORMULATION, BY TYPE 2015 – 2024 (USD MILLION)
Table 68 NORTH AMERICA NANOPARTICLES COLLOIDAL DISPERSIONS DRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)
Table 69 NORTH AMERICA MICROPARTICLESDRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)
Table 70 NORTH AMERICAINJECTable DRUG DELIVERY MARKET, BY APPLICATION,2015 – 2024 (USD MILLION)
Table 71 NORTH AMERICA AUTOIMMUNE DISEASES INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
Table 72 NORTH AMERICA HORMONAL DISORDERS INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
Table 73 NORTH AMERICA OTHERS INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
Table 74 NORTH AMERICA INJECTable DRUG DELIVERY MARKET, BY USAGE PATTERN, 2015– 2024 (USD MILLION)
Table 75 NORTH AMERICA INJECTable DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION, 2015– 2024 (USD MILLION)
Table 76 NORTH AMERICA INJECTable DRUG DELIVERY MARKET, BY END USER, 2015– 2024 (USD MILLION)
Table 77 NORTH AMERICA INJECTable DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL 2015– 2024 (USD MILLION)
Table 78 U.S. INJECTable DRUG DELIVERY MARKET, BY TYPE, 2015 – 2024(USD MILLION)
Table 79 U.S. INJECTable DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 80 U.S. CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY MATERIAL, 2015 – 2024(USD MILLION)
Table 81 U.S. CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION)
Table 82 U.S. CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 83 U.S. SELF INJECTION DEVICE MARKET, BY TYPE,2015 – 2024(USD MILLION)
Table 84 U.S. NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)
Table 85 U.S. NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)
Table 86 U.S. NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 87 U.S. AUTO INJECTORS DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)
Table 88 U.S. AUTO INJECTORS DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)
Table 89 U.S. AUTO INJECTORS DEVICE MARKET, BY DESIGN, 2015 – 2024(USD MILLION)
Table 90 U.S. AUTO INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 91 U.S. PEN INJECTORS DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)
Table 92 U.S. PEN INJECTORS DEVICE MARKET, BY DESIGN,2015 – 2024(USD MILLION)
Table 93 U.S. PEN INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 94 U.S. INJECTable DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE, 2015– 2024 (USD MILLION)
Table 95 U.S. CONVENTIONAL DRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)
Table 96 U.S. NOVEL DRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)
Table 97 U.S. COLLOIDAL DISPERSION DRUG DELIVERY FORMULATION, BY TYPE 2015 – 2024 (USD MILLION)
Table 98 U.S. NANOPARTICLES COLLOIDAL DISPERSIONS NOVELDRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)
Table 99 U.S. MICROPARTICLES NOVEL DRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)
Table 100 U.S. INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
Table 101 U.S. AUTOIMMUNE DISEASES INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
Table 102 U.S. HORMONAL DISORDERS INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
Table 103 U.S. OTHERS INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
Table 104 U.S. INJECTable DRUG DELIVERY MARKET, BY USAGE PATTERN, 2015– 2024 (USD MILLION)
Table 105 U.S. INJECTable DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION, 2015– 2024 (USD MILLION)
Table 106 U.S. INJECTable DRUG DELIVERY MARKET, BY END USER, 2015– 2024 (USD MILLION)
Table 107 U.S. INJECTable DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL 2015– 2024 (USD MILLION)
Table 108 CANADA INJECTable DRUG DELIVERY MARKET, BY TYPE, 2015 – 2024(USD MILLION)
Table 109 CANADA INJECTable DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 110 CANADA CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY MATERIAL, 2015 – 2024(USD MILLION)
Table 111 CANADA CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION)
Table 112 CANADA CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 113 CANADA SELF INJECTION DEVICE MARKET, BY TYPE, 2015 – 2024(USD MILLION)
Table 114 CANADA NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)
Table 115 CANADA NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)
Table 116 CANADA NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 117 CANADA AUTO INJECTORS DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)
Table 118 CANADA AUTO INJECTORS DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)
Table 119 CANADA AUTO INJECTORS DEVICE MARKET, BY DESIGN, 2015 – 2024(USD MILLION)
Table 120 CANADA AUTO INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 121 CANADA PEN INJECTORS DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)
Table 122 CANADA PEN INJECTORS DEVICE MARKET, BY DESIGN, 2015 – 2024(USD MILLION)
Table 123 CANADA PEN INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 124 CANADA INJECTable DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE, 2015– 2024 (USD MILLION)
Table 125 CANADA CONVENTIONAL DRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)
Table 126 CANADA NOVEL DRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)
Table 127 CANADA COLLOIDAL DISPERSION DRUG DELIVERY FORMULATION, BY TYPE 2015 – 2024 (USD MILLION)
Table 128 CANADA NANOPARTICLES COLLOIDAL DISPERSIONS DRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)
Table 129 CANADA MICROPARTICLES DRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)
Table 130 CANADA INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
Table 131 CANADA AUTOIMMUNE DISEASES INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
Table 132 CANADA HORMONAL DISORDERS INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
Table 133 CANADA OTHERS INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
Table 134 CANADA INJECTable DRUG DELIVERY MARKET, BY USAGE PATTERN, 2015– 2024 (USD MILLION)
Table 135 CANADA INJECTable DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION, 2015– 2024 (USD MILLION)
Table 136 CANADA INJECTable DRUG DELIVERY MARKET, BY END USER, 2015– 2024 (USD MILLION)
Table 137 CANADA INJECTable DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL 2015– 2024 (USD MILLION)
Table 138 MEXICO INJECTable DRUG DELIVERY MARKET, BY TYPE, 2015 – 2024(USD MILLION)
Table 139 MEXICO INJECTable DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 140 MEXICO CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY MATERIAL, 2015 – 2024(USD MILLION)
Table 141 MEXICO CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION)
Table 142 MEXICO CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 143 MEXICO SELF INJECTION DEVICE MARKET, BY TYPE, 2015 – 2024(USD MILLION)
Table 144 MEXICO NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)
Table 145 MEXICO NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)
Table 146 MEXICO NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 147 MEXICO AUTO INJECTORS DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)
Table 148 MEXICO AUTO INJECTORS DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)
Table 149 MEXICO AUTO INJECTORS DEVICE MARKET, BY DESIGN, 2015 – 2024(USD MILLION)
Table 150 MEXICO AUTO INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 151 MEXICO PEN INJECTORS DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)
Table 152 MEXICO PEN INJECTORS DEVICE MARKET, BY DESIGN, 2015 – 2024(USD MILLION)
Table 153 MEXICO PEN INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 154 MEXICO INJECTable DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE, 2015– 2024 (USD MILLION)
Table 155 MEXICO CONVENTIONAL DRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)
Table 156 MEXICO NOVEL DRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)
Table 157 MEXICO COLLOIDAL DISPERSION DRUG DELIVERY FORMULATION, BY TYPE 2015 – 2024 (USD MILLION)
Table 158 MEXICO NANOPARTICLES COLLOIDAL DISPERSIONS DRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)
Table 159 MEXICO MICROPARTICLES DRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)
Table 1 EXAMPLES OF TECHNOLOGICAL ADVANCEMENTS ()(2013- 2017)
Table 2 NUMBER OF NEEDLESTICK INJURIES
Table 3 LIST OF PRODUCT RECALL DRUGS
Table 4 LIST OF DIFFERENT TYPES OF APPROVAL FOR DIFFERENT COUNTRIES
Table 5 GLOBAL INJECTable DRUG DELIVERY MARKET, BY TYPE, 2015 – 2024(USD MILLION)
Table 6 GLOBAL INJECTable DRUG DELIVERY DEVICES MARKET, BY TYPE, 2015 – 2024 (USD MILLION)
Table 7 GLOBAL CONVENTIONAL DRUG DELIVERY MARKET, BY MATERIAL, 2015 – 2024 (USD MILLION)
Table 8 GLOBAL CONVENTIONAL DRUG DELIVERY MARKET, BY PRODUCT, 2015 – 2024 (USD MILLION)
Table 9 GLOBAL CONVENTIONAL DRUG DELIVERY MARKET, BY USABILITY, 2015 – 2024 (USD MILLION)
Table 10 GLOBAL SELF INJECTION DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 11 GLOBAL NEEDLE FREE INJECTOR DEVICES MARKET, BY PRODUCT, 2015 – 2024 (USD MILLION)
Table 12 GLOBAL NEEDLE FREE INJECTOR DEVICES MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)
Table 13 GLOBAL NEEDLE FREE INJECTORS DEVICE ARKET, BY USABILITY, 2015 – 2024 (USD MILLION)
Table 14 GLOBAL AUTO INJECTOR DEVICES MARKET, BY PRODUCT, 2015 – 2024 (USD MILLION)
Table 15 GLOBAL AUTO INJECTOR DEVICES MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)
Table 16 GLOBAL AUTO INJECTOR DEVICES MARKET, BY DESIGN, 2015 – 2024 (USD MILLION)
Table 17 GLOBAL AUTO INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024 (USD MILLION)
Table 18 GLOBAL PEN INJECTOR DEVICES MARKET, BY PRODUCT, 2015 – 2024 (USD MILLION)
Table 19 GLOBAL PEN INJECTOR DEVICES MARKET, BY DESIGN, 2015 – 2024 (USD MILLION)
Table 20 GLOBAL PEN INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024 (USD MILLION)
Table 21 GLOBAL INJECTable DRUG DELIVERY FORMULATION MARKET, BY TYPE, 2015 – 2024 (USD MILLION)
Table 22 LIST OF SOME OF THE LYOPHILIZED FORMULATIONS
Table 23 LIST OF SOME OF THE EMULSIONS
Table 24 GLOBAL CONVENTIONAL DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 25 GLOBAL NOVEL DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE,2015 – 2024 (USD MILLION)
Table 26 GLOBAL COLLOIDAL NOVEL DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 27 LIST OF SOME OF THE NIOSOMES
Table 28 LIST OF SOME OF THE POLYMERIC MIXED MICELLES DRUG MANUFACTURER
Table 29 LIST OF NANOSUSPENSION DRUG MANUFACTURER
Table 30 LIST OF SOME OF THE NANOEMULSIONS/MICROEMULSIONS DRUG MANUFACTURER
Table 31 LIST OF SOME OF THE SOLID LIPID NANOPARTICLES DRUG MANUFACTURER
Table 32 GLOBAL NANOPARTICLE COLLOIDAL DRUG DELIVERY FORMULATION MARKET, BY PRODUCT, 2015 – 2024 (USD MILLION)
Table 33 LIST OF SOME OF THE MICROSPHERES DRUG MANUFACTURER
Table 34 GLOBAL MICROPARTICLES COLLOIDAL NOVEL DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 35 LIST OF SOME OF THE FIRST GENERATION LONG ACTING INJECTION
Table 36 LIST OF SOME OF THE SECOND GENERATION LONG ACTING INJECTION:
Table 37 GLOBAL INJECTable DRUG DELIVERY APPLICATION MARKET, BY TYPE, 2015 – 2024 (USD MILLION)
Table 38 GLOBAL HORMONAL DISORDERS INJECTable DRUG DELIVERY APPLICATION MARKET, BY TYPE, 2015 – 2024 (USD BILLION)
Table 39 GLOBAL AUTOIMMUNE DISEASE INJECTable DRUG DELIVERY APPLICATION MARKET, BY TYPE, 2015 – 2024 (USD BILLION)
Table 40 LIST OF ORPHAN DISEASE IN INDIA (2010)
Table 41 GLOBAL OTHERS INJECTable DRUG DELIVERY APPLICATION MARKET, BY TYPE, 2015 – 2024 (USD BILLION)
Table 42 GLOBALINJECTable DRUG DELIVERY USAGE PATTERN MARKET, BY TYPE, 2015 – 2024 (USD MILLION)
Table 43 GLOBAL INJECTable DRUG DELIVERY MODE OF ADMINISTRATION MARKET, BY TYPE, 2015 – 2024 (USD MILLION)
Table 44 GLOBAL INJECTable DRUG DELIVERY MARKET, BY END USER, 2015– 2024 (USD MILLION)
Table 45 GLOBAL INJECTable DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
Table 46 GLOBAL INJECTable DRUG DELIVERY MARKET, BY GEOGRAPHY, 2015 – 2024 (USD MILLION)
Table 47 NORTH AMERICA INJECTable DRUG DELIVERY MARKET, BY COUNTRY, 2015 – 2024 (USD MILLION)
Table 48 NORTH AMERICA INJECTable DRUG DELIVERY MARKET, BY TYPE, 2015 – 2024(USD MILLION)
Table 49 NORTH AMERICA INJECTable DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 50 NORTH AMERICA CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY MATERIAL,2015 – 2024(USD MILLION)
Table 51 NORTH AMERICA CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION)
Table 52 NORTH AMERICA CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 53 NORTH AMERICA SELF INJECTION DEVICE MARKET, BY TYPE, 2015 – 2024(USD MILLION)
Table 54 NORTH AMERICA NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY PRODUCT,2015 – 2024(USD MILLION)
Table 55 NORTH AMERICA NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)
Table 56 NORTH AMERICA NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 57 NORTH AMERICA AUTO INJECTORSDEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)
Table 58 NORTH AMERICA AUTO INJECTORS DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)
Table 59 NORTH AMERICA AUTO INJECTORS DEVICE MARKET, BY DESIGN, 2015 – 2024(USD MILLION)
Table 60 NORTH AMERICA AUTO INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 61 NORTH AMERICA PEN INJECTORS DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)
Table 62 NORTH AMERICA PEN INJECTORS DEVICE MARKET, BY DESIGN, 2015 – 2024(USD MILLION)
Table 63 NORTH AMERICA PEN INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 64 NORTH AMERICA INJECTable DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE, 2015– 2024 (USD MILLION)
Table 65 NORTH AMERICA CONVENTIONALDRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)
Table 66 NORTH AMERICA NOVELDRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)
Table 67 NORTH AMERICA COLLOIDALDISPERSION DRUG DELIVERY FORMULATION, BY TYPE 2015 – 2024 (USD MILLION)
Table 68 NORTH AMERICA NANOPARTICLES COLLOIDAL DISPERSIONS DRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)
Table 69 NORTH AMERICA MICROPARTICLESDRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)
Table 70 NORTH AMERICAINJECTable DRUG DELIVERY MARKET, BY APPLICATION,2015 – 2024 (USD MILLION)
Table 71 NORTH AMERICA AUTOIMMUNE DISEASES INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
Table 72 NORTH AMERICA HORMONAL DISORDERS INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
Table 73 NORTH AMERICA OTHERS INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
Table 74 NORTH AMERICA INJECTable DRUG DELIVERY MARKET, BY USAGE PATTERN, 2015– 2024 (USD MILLION)
Table 75 NORTH AMERICA INJECTable DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION, 2015– 2024 (USD MILLION)
Table 76 NORTH AMERICA INJECTable DRUG DELIVERY MARKET, BY END USER, 2015– 2024 (USD MILLION)
Table 77 NORTH AMERICA INJECTable DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL 2015– 2024 (USD MILLION)
Table 78 U.S. INJECTable DRUG DELIVERY MARKET, BY TYPE, 2015 – 2024(USD MILLION)
Table 79 U.S. INJECTable DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 80 U.S. CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY MATERIAL, 2015 – 2024(USD MILLION)
Table 81 U.S. CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION)
Table 82 U.S. CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 83 U.S. SELF INJECTION DEVICE MARKET, BY TYPE,2015 – 2024(USD MILLION)
Table 84 U.S. NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)
Table 85 U.S. NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)
Table 86 U.S. NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 87 U.S. AUTO INJECTORS DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)
Table 88 U.S. AUTO INJECTORS DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)
Table 89 U.S. AUTO INJECTORS DEVICE MARKET, BY DESIGN, 2015 – 2024(USD MILLION)
Table 90 U.S. AUTO INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 91 U.S. PEN INJECTORS DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)
Table 92 U.S. PEN INJECTORS DEVICE MARKET, BY DESIGN,2015 – 2024(USD MILLION)
Table 93 U.S. PEN INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 94 U.S. INJECTable DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE, 2015– 2024 (USD MILLION)
Table 95 U.S. CONVENTIONAL DRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)
Table 96 U.S. NOVEL DRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)
Table 97 U.S. COLLOIDAL DISPERSION DRUG DELIVERY FORMULATION, BY TYPE 2015 – 2024 (USD MILLION)
Table 98 U.S. NANOPARTICLES COLLOIDAL DISPERSIONS NOVELDRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)
Table 99 U.S. MICROPARTICLES NOVEL DRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)
Table 100 U.S. INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
Table 101 U.S. AUTOIMMUNE DISEASES INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
Table 102 U.S. HORMONAL DISORDERS INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
Table 103 U.S. OTHERS INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
Table 104 U.S. INJECTable DRUG DELIVERY MARKET, BY USAGE PATTERN, 2015– 2024 (USD MILLION)
Table 105 U.S. INJECTable DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION, 2015– 2024 (USD MILLION)
Table 106 U.S. INJECTable DRUG DELIVERY MARKET, BY END USER, 2015– 2024 (USD MILLION)
Table 107 U.S. INJECTable DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL 2015– 2024 (USD MILLION)
Table 108 CANADA INJECTable DRUG DELIVERY MARKET, BY TYPE, 2015 – 2024(USD MILLION)
Table 109 CANADA INJECTable DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 110 CANADA CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY MATERIAL, 2015 – 2024(USD MILLION)
Table 111 CANADA CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION)
Table 112 CANADA CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 113 CANADA SELF INJECTION DEVICE MARKET, BY TYPE, 2015 – 2024(USD MILLION)
Table 114 CANADA NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)
Table 115 CANADA NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)
Table 116 CANADA NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 117 CANADA AUTO INJECTORS DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)
Table 118 CANADA AUTO INJECTORS DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)
Table 119 CANADA AUTO INJECTORS DEVICE MARKET, BY DESIGN, 2015 – 2024(USD MILLION)
Table 120 CANADA AUTO INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 121 CANADA PEN INJECTORS DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)
Table 122 CANADA PEN INJECTORS DEVICE MARKET, BY DESIGN, 2015 – 2024(USD MILLION)
Table 123 CANADA PEN INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 124 CANADA INJECTable DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE, 2015– 2024 (USD MILLION)
Table 125 CANADA CONVENTIONAL DRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)
Table 126 CANADA NOVEL DRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)
Table 127 CANADA COLLOIDAL DISPERSION DRUG DELIVERY FORMULATION, BY TYPE 2015 – 2024 (USD MILLION)
Table 128 CANADA NANOPARTICLES COLLOIDAL DISPERSIONS DRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)
Table 129 CANADA MICROPARTICLES DRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)
Table 130 CANADA INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
Table 131 CANADA AUTOIMMUNE DISEASES INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
Table 132 CANADA HORMONAL DISORDERS INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
Table 133 CANADA OTHERS INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
Table 134 CANADA INJECTable DRUG DELIVERY MARKET, BY USAGE PATTERN, 2015– 2024 (USD MILLION)
Table 135 CANADA INJECTable DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION, 2015– 2024 (USD MILLION)
Table 136 CANADA INJECTable DRUG DELIVERY MARKET, BY END USER, 2015– 2024 (USD MILLION)
Table 137 CANADA INJECTable DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL 2015– 2024 (USD MILLION)
Table 138 MEXICO INJECTable DRUG DELIVERY MARKET, BY TYPE, 2015 – 2024(USD MILLION)
Table 139 MEXICO INJECTable DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
Table 140 MEXICO CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY MATERIAL, 2015 – 2024(USD MILLION)
Table 141 MEXICO CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION)
Table 142 MEXICO CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 143 MEXICO SELF INJECTION DEVICE MARKET, BY TYPE, 2015 – 2024(USD MILLION)
Table 144 MEXICO NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)
Table 145 MEXICO NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)
Table 146 MEXICO NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 147 MEXICO AUTO INJECTORS DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)
Table 148 MEXICO AUTO INJECTORS DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)
Table 149 MEXICO AUTO INJECTORS DEVICE MARKET, BY DESIGN, 2015 – 2024(USD MILLION)
Table 150 MEXICO AUTO INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 151 MEXICO PEN INJECTORS DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)
Table 152 MEXICO PEN INJECTORS DEVICE MARKET, BY DESIGN, 2015 – 2024(USD MILLION)
Table 153 MEXICO PEN INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
Table 154 MEXICO INJECTable DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE, 2015– 2024 (USD MILLION)
Table 155 MEXICO CONVENTIONAL DRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)
Table 156 MEXICO NOVEL DRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)
Table 157 MEXICO COLLOIDAL DISPERSION DRUG DELIVERY FORMULATION, BY TYPE 2015 – 2024 (USD MILLION)
Table 158 MEXICO NANOPARTICLES COLLOIDAL DISPERSIONS DRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)
Table 159 MEXICO MICROPARTICLES DRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)
LIST OF FIGURES
Figure 1 GLOBAL INJECTable DRUG DELIVERY MARKET: SEGMENTATION
Figure 2 GLOBAL INJECTable DRUG DELIVERY MARKET: GEOGRAPHIC SCOPE
Figure 3 GLOBAL INJECTable DRUG DELIVERY MARKET: DATA TRIANGULATION
Figure 4 GLOBAL INJECTable DRUG DELIVERY MARKET: RESEARCH SNAPSHOT
Figure 5 GLOBAL INJECTable DRUG DELIVERY MARKET: BOTTOM UP APPROACH
Figure 6 GLOBAL INJECTable DRUG DELIVERY MARKET: TOP DOWN APPROACH
Figure 7 GLOBAL INJECTable DRUG DELIVERY MARKET: INTERVIEW DEMOGRAPHICS
Figure 8 FIGURE: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE INJECTable DRUG DELIVERY MARKET
Figure 9 NORTH AMERICA IS EXPECTED TO DOMINATE THE MARKET FOR INJECTable DRUG DELIVERY IN 2016 AND APAC IS EXPECTED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD TO 2024
Figure 10 TECHNOLOGICAL DEVELOPMENT AND INCREASING PREVALENCE OF CHRONIC DISEASES ARE EXPECTED TO DRIVE THE MARKET FOR INJECTable DRUG DELIVERY IN THE FORECAST PERIOD 2017 TO 2024
Figure 11 INJECTable DRUG DELIVERY FORMULATION MARKET SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL INJECTable DRUG DELIVERY MARKET IN 2017 & 2024
Figure 12 NORTH AMERICA IS THE HIGHEST GROWING AND MOST PROFITable REVENUE POCKETS FOR INJECTable DRUG DELIVERY MANUFACTURERS IN THE FORECAST PERIOD TO 2024
Figure 13 GLOBAL INJECTable DRUG DELIVERY MARKET: BY TYPE, SNAPSHOT 2016
Figure 14 GLOBAL INJECTable DRUG DELIVERY MARKET: BY APPLICATION, SNAPSHOT 2016
Figure 15 GLOBAL INJECTable DRUG DELIVERY MARKET: BY USAGE PATTERN, SNAPSHOT 2016
Figure 16 GLOBAL INJECTable DRUG DELIVERY MARKET: BY MODE OF ADMINISTRATION, SNAPSHOT 2016
Figure 17 GLOBAL INJECTable DRUG DELIVERY MARKET DOMINATED BY HOSPITAL AND CLIINICS SEGMENT
Figure 18 GLOBAL INJECTable DRUG DELIVERYMARKET:BY END-USER, SNAPSHOT 2016
Figure 19 GLOBAL INJECTable DRUG DELIVERY MARKET: BY DISTRIBUTION CHANNEL, SNAPSHOT 2016
Figure 20 NORTH AMERICA INJECTable DRUG DELIVERY MARKET SNAPSHOT (2017)
Figure 21 EUROPEAN INJECTable DRUG DELIVERY MARKET SNAPSHOT (2017)
Figure 22 ASIA GLOBAL INJECTable DRUG DELIVERY MARKET SNAPSHOT (2017)
Figure 23 SOUTH AMERICA INJECTable DRUG DELIVERY MARKET SNAPSHOT (2017)
Figure 24 MEA GLOBAL INJECTable DRUG DELIVERY MARKET SNAPSHOT (2017)
Figure 25 GLOBAL INJECTable DRUG DELIVERY MARKET: COMPANY SHARE 2016 (%)
Figure 26 BECTON, DICKINSON AND COMPANY: SWOT (STRENGTH, WEAKNESS, OPPORTUNITIES AND THREATS)
Figure 27 BECTON, DICKINSOM AND COMPANY: REVENUE ANALYSIS
Figure 28 PFIZER, INC.: SWOT (STRENGTH, WEAKNESS, OPPORTUNITIES AND THREATS)
Figure 29 PFIZER, INC.: REVENUE ANALYSIS
Figure 30 BAXTER INTERNATIONAL INC.: SWOT (STRENGTH, WEAKNESS, OPPORTUNITIES AND THREATS)
Figure 31 BAXTER INTERNATIONAL, INC.: REVENUE ANALYSIS
Figure 32 GERRESHEIMER AG: REVENUE ANALYSIS
Figure 33 SCHOTT AG INC.: REVENUE ANALYSIS
Figure 34 ALKERMES INC.: REVENUE ANALYSIS
Figure 35 ANTARES PHARMA: REVENUE ANALYSIS
Figure 36 BESPAK: REVENUE ANALYSIS
Figure 37 ELCAM MEDICAL: REVENUE ANALYSIS
Figure 38 ELI LILLY AND COMPANY: SWOT (STRENGTH, WEAKNESS, OPPORTUNITIES AND THREATS)
Figure 39 ELI LILLY AND COMPANY: REVENUE ANALYSIS
Figure 40 HASELMEIER: REVENUE ANALYSIS
Figure 41 MYLAN N.V.: REVENUE ANALYSIS
Figure 42 NOVO NORDISK: REVENUE ANALYSIS
Figure 43 OWEN MUMFORD LTD: REVENUE ANALYSIS
Figure 44 SANDOZ INTERNATIONAL GMBH: REVENUE ANALYSIS
Figure 45 SANOFI: REVENUE ANALYSIS
Figure 46 TERUMO CORPORATION: REVENUE ANALYSIS
Figure 47 TEVA PHARMACEUTICAL: SWOT (STRENGTH, WEAKNESS, OPPORTUNITIES AND THREATS)
Figure 48 TEVA PHARMACEUTICAL: REVENUE ANALYSIS
Figure 49 WEST PHARMACEUTICAL SERVICES, INC: REVENUE ANALYSIS
Figure 50 YPSOMED HOLDING AG: REVENUE ANALYSIS
Figure 1 GLOBAL INJECTable DRUG DELIVERY MARKET: SEGMENTATION
Figure 2 GLOBAL INJECTable DRUG DELIVERY MARKET: GEOGRAPHIC SCOPE
Figure 3 GLOBAL INJECTable DRUG DELIVERY MARKET: DATA TRIANGULATION
Figure 4 GLOBAL INJECTable DRUG DELIVERY MARKET: RESEARCH SNAPSHOT
Figure 5 GLOBAL INJECTable DRUG DELIVERY MARKET: BOTTOM UP APPROACH
Figure 6 GLOBAL INJECTable DRUG DELIVERY MARKET: TOP DOWN APPROACH
Figure 7 GLOBAL INJECTable DRUG DELIVERY MARKET: INTERVIEW DEMOGRAPHICS
Figure 8 FIGURE: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE INJECTable DRUG DELIVERY MARKET
Figure 9 NORTH AMERICA IS EXPECTED TO DOMINATE THE MARKET FOR INJECTable DRUG DELIVERY IN 2016 AND APAC IS EXPECTED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD TO 2024
Figure 10 TECHNOLOGICAL DEVELOPMENT AND INCREASING PREVALENCE OF CHRONIC DISEASES ARE EXPECTED TO DRIVE THE MARKET FOR INJECTable DRUG DELIVERY IN THE FORECAST PERIOD 2017 TO 2024
Figure 11 INJECTable DRUG DELIVERY FORMULATION MARKET SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL INJECTable DRUG DELIVERY MARKET IN 2017 & 2024
Figure 12 NORTH AMERICA IS THE HIGHEST GROWING AND MOST PROFITable REVENUE POCKETS FOR INJECTable DRUG DELIVERY MANUFACTURERS IN THE FORECAST PERIOD TO 2024
Figure 13 GLOBAL INJECTable DRUG DELIVERY MARKET: BY TYPE, SNAPSHOT 2016
Figure 14 GLOBAL INJECTable DRUG DELIVERY MARKET: BY APPLICATION, SNAPSHOT 2016
Figure 15 GLOBAL INJECTable DRUG DELIVERY MARKET: BY USAGE PATTERN, SNAPSHOT 2016
Figure 16 GLOBAL INJECTable DRUG DELIVERY MARKET: BY MODE OF ADMINISTRATION, SNAPSHOT 2016
Figure 17 GLOBAL INJECTable DRUG DELIVERY MARKET DOMINATED BY HOSPITAL AND CLIINICS SEGMENT
Figure 18 GLOBAL INJECTable DRUG DELIVERYMARKET:BY END-USER, SNAPSHOT 2016
Figure 19 GLOBAL INJECTable DRUG DELIVERY MARKET: BY DISTRIBUTION CHANNEL, SNAPSHOT 2016
Figure 20 NORTH AMERICA INJECTable DRUG DELIVERY MARKET SNAPSHOT (2017)
Figure 21 EUROPEAN INJECTable DRUG DELIVERY MARKET SNAPSHOT (2017)
Figure 22 ASIA GLOBAL INJECTable DRUG DELIVERY MARKET SNAPSHOT (2017)
Figure 23 SOUTH AMERICA INJECTable DRUG DELIVERY MARKET SNAPSHOT (2017)
Figure 24 MEA GLOBAL INJECTable DRUG DELIVERY MARKET SNAPSHOT (2017)
Figure 25 GLOBAL INJECTable DRUG DELIVERY MARKET: COMPANY SHARE 2016 (%)
Figure 26 BECTON, DICKINSON AND COMPANY: SWOT (STRENGTH, WEAKNESS, OPPORTUNITIES AND THREATS)
Figure 27 BECTON, DICKINSOM AND COMPANY: REVENUE ANALYSIS
Figure 28 PFIZER, INC.: SWOT (STRENGTH, WEAKNESS, OPPORTUNITIES AND THREATS)
Figure 29 PFIZER, INC.: REVENUE ANALYSIS
Figure 30 BAXTER INTERNATIONAL INC.: SWOT (STRENGTH, WEAKNESS, OPPORTUNITIES AND THREATS)
Figure 31 BAXTER INTERNATIONAL, INC.: REVENUE ANALYSIS
Figure 32 GERRESHEIMER AG: REVENUE ANALYSIS
Figure 33 SCHOTT AG INC.: REVENUE ANALYSIS
Figure 34 ALKERMES INC.: REVENUE ANALYSIS
Figure 35 ANTARES PHARMA: REVENUE ANALYSIS
Figure 36 BESPAK: REVENUE ANALYSIS
Figure 37 ELCAM MEDICAL: REVENUE ANALYSIS
Figure 38 ELI LILLY AND COMPANY: SWOT (STRENGTH, WEAKNESS, OPPORTUNITIES AND THREATS)
Figure 39 ELI LILLY AND COMPANY: REVENUE ANALYSIS
Figure 40 HASELMEIER: REVENUE ANALYSIS
Figure 41 MYLAN N.V.: REVENUE ANALYSIS
Figure 42 NOVO NORDISK: REVENUE ANALYSIS
Figure 43 OWEN MUMFORD LTD: REVENUE ANALYSIS
Figure 44 SANDOZ INTERNATIONAL GMBH: REVENUE ANALYSIS
Figure 45 SANOFI: REVENUE ANALYSIS
Figure 46 TERUMO CORPORATION: REVENUE ANALYSIS
Figure 47 TEVA PHARMACEUTICAL: SWOT (STRENGTH, WEAKNESS, OPPORTUNITIES AND THREATS)
Figure 48 TEVA PHARMACEUTICAL: REVENUE ANALYSIS
Figure 49 WEST PHARMACEUTICAL SERVICES, INC: REVENUE ANALYSIS
Figure 50 YPSOMED HOLDING AG: REVENUE ANALYSIS
